Discovery 2010

Teodor Aastrup, CEO , Attana AB will be presenting on: Kinetics on cells – bridging the gap between traditional biosensors and cell-based assays The development of new pharmaceutical antibodies is a long and expensive process with sharply increasing costs during clinical trials. Widespread technologies to measure molecular interactions using purified target and ligand are powerful, but often oversimplify the interaction. This is particularly true for membrane proteins which need a membrane environment to retain their biological activity. At the same time, bioassays measure the biological effects but do not give much information regarding the dynamics of interactions. This leaves a gap in the information base which can be filled by molecular interaction measurements directly on cells. Thus, an immense improvement within the field would be to measure the true drug interaction with the native target in its biological context, the cell. Studying the interaction towards the target in its native context promises better estimates of efficacy, dosing and safety, lowering the reported 50% fall-out in Phase III. The Attana Cell™ 200 is a QCM based biosensor that provides highly informative data about drug candidates in preclinical stage, thus improving selection and reducing the risk of late failures. Two typical examples where the Attana Cell 200 proved to be beneficial will be presented; 1) study of a glycoprotein to be used as a diagnostic tool for early detection of metastatic colorectal cancer, 2) characterization of modified Herceptin® designed for targeted immunotherapy in cases of breast and ovarian carcinomas. Dr. Staffan Grenklo will also be available for meetings with conference participants. Event webpage: http://www.thediscoverysummit.com/